Saurabh Dahiya

1 week ago | cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour

At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, Galapagos presented new data regarding GLPG5101, an investigational. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy product. During the conference, CGTLive® interviewed Omotayo Fasan, MRCP, DTM&H, MBBS, the head of the clinical development program at Galapagos, about the findings.

1 week ago | cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour

At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, data are being presented from a phase 1 clinical trial (NCT04989803) evaluating Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory (r/r) B-cell lymphoma.

2 weeks ago | cgtlive.com | Saurabh Dahiya |Ashling Wahner |Caroline Seymour

This video originally appeared on our sister site, OncLive®. At the highest dose level in CAR naive patients, we observed an objective overall response rate of 87% and a complete remission rate of 78%. Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) B-cell lymphoma in a phase 1 clinical trial (NCT04989803).

Jan 30, 2025 | onclive.com | Shyam Patel |Saurabh Dahiya

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, we had the pleasure of speaking with Saurabh Dahiya, MD, FACP, and Shyam A.

May 16, 2024 | onclive.com | Saurabh Dahiya

Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division, discusses the significance of the FDA approval of lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed/refractory follicular lymphoma (FL).